Curi Bio Presentation: Innovative 3D In Vitro Platforms to Create Scalable Human iPSC-derived 3D Engineered Skeletal Muscle & Cardiac Tissue Models for Drug Discovery
Thursday, May 30, 2024 03:15 PM - 03:45 PM
Exhibit Hall - Theatre A
Global Showcase Presentation
Presenter
Curi Bio will present its Mantarray platform, which represents an easy-to-use, flexible and scalable system for generating 3D muscle organoids at medium-throughput with the ability to measure contractility in parallel.
The platform features a novel method of casting 3D tissues that can be easily performed by nearly any cell biology researcher and can be readily adapted to a variety of cell lines and extracellular matrices.
In addition, the platform’s novel magnetic sensing modality permits contractility measurement of 24 tissues in parallel and in real time, while the cloud data analysis portal takes the guesswork out of analyzing and comparing results across experiments.
A basic overview of the technology will be provided, along with application examples across various use cases. Cardiac applications will focus on the assessment of drug toxicity in iPSC-derived engineered heart tissues (EHTs) for acute proarrhythmic compounds as well as for chronic structural cardiotoxicants.
Data on primary and iPSC-derived skeletal muscle constructs will also be presented, including disease phenotype stratification in muscle diseases like muscular dystrophy.
Session Objectives:
• Generation of high quality human iPSC-derived myoblasts for use in 3D tissue engineering
• Validation and quality control to ensure consistency and ease of use in a ready-to-cast from cryopreservation format
• The implementation of 3D organoids using a scalable approach
• How to use these systems for toxicity screening and disease modeling
- Shawn Luttrell, PhD, Product Manager of Cell & Tissue Models, Curi Bio, USA
Curi Bio will present its Mantarray platform, which represents an easy-to-use, flexible and scalable system for generating 3D muscle organoids at medium-throughput with the ability to measure contractility in parallel.
The platform features a novel method of casting 3D tissues that can be easily performed by nearly any cell biology researcher and can be readily adapted to a variety of cell lines and extracellular matrices.
In addition, the platform’s novel magnetic sensing modality permits contractility measurement of 24 tissues in parallel and in real time, while the cloud data analysis portal takes the guesswork out of analyzing and comparing results across experiments.
A basic overview of the technology will be provided, along with application examples across various use cases. Cardiac applications will focus on the assessment of drug toxicity in iPSC-derived engineered heart tissues (EHTs) for acute proarrhythmic compounds as well as for chronic structural cardiotoxicants.
Data on primary and iPSC-derived skeletal muscle constructs will also be presented, including disease phenotype stratification in muscle diseases like muscular dystrophy.
Session Objectives:
• Generation of high quality human iPSC-derived myoblasts for use in 3D tissue engineering
• Validation and quality control to ensure consistency and ease of use in a ready-to-cast from cryopreservation format
• The implementation of 3D organoids using a scalable approach
• How to use these systems for toxicity screening and disease modeling
SPONSORED BY:
